Monoclonal antibody therapeutics: history and future
Monoclonal antibody therapeutics: history and future
复制标题
DOI：
10.1016/j.coph.2012.08.001
复制
发表时间：
2012-10-01
影响因子：
4
通讯作者：
de Haan, Lolke
中科院分区：
文献类型：
--
作者：
Buss, Nicholas A. P. S.;Henderson, Simon J.;de Haan, Lolke
在过去的三十年里，克隆抗体从科学工具到强大的人类疗法发生了戏剧性的转变。目前，约有30种治疗性单抗在美国和欧洲以各种适应症上市，2010年仅在美国的销售额就达到约185亿美元。这篇综述描述了抗体工程如何给药物发现带来革命性的变化，以及在单抗治疗领域中被认为是未来发展的关键领域。
Over the last three decades, monoclonal antibodies have made a dramatic transformation from scientific tools to powerful human therapeutics. At present, approximately 30 therapeutic monoclonal antibodies are marketed in the United States and Europe in a variety of indications, with sales in the US alone reaching approximately $18.5 billion in 2010. This review describes how antibody engineering has revolutionized drug discovery and what are considered the key areas for future development in the monoclonal antibody therapy field.